Wolfgang Miesbach: CMA CAR-T Induces Immune Reset and Durable Remission in Refractory ITP – EHA 2026 Late-Breaking Update
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Jinhui Shu et al, adding։
“Looking ahead to EHA 2026 next week, I am particularly interested in an upcoming late-breaking presentation:
- BCMA CAR-T Cell Therapy Induces Comprehensive Immune Resetting and Durable Remission in Refractory Primary Immune Thrombocytopenia
Targeting plasma cells and pathogenic antibody production represents a promising mechanistic shift beyond traditional B-cell–directed approaches.
It will be exciting to see how these strategies translate into clinical responses and immune modulation.”
Title: BCMA CAR-T cell therapy induces comprehensive immune resetting and durable remission in refractory primary immune thrombocytopenia
Authors: Jinhui Shu, Min Xu, Wei Xie, Lin Liu, Peiru Li, Hongjian Li, James Bussel, Yu Hu, Heng Mei
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 5, 2026, 15:34Ney Carter Borges: Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease – Lessons From the TRACK Trial
-
Jun 5, 2026, 15:29Nethuki Kulasinghe: Sequential Anticoagulation in Postpartum Iliocaval Thrombosis With Submassive PE and HIT
-
Jun 5, 2026, 15:23Michelle Leona Cecil: Microhealth – Digital Health Platform for Bleeding Disorders Community
-
Jun 5, 2026, 15:23Claudia Rizk: Collaborative Endovascular Intervention Enables Successful Treatment of Acute Limb Ischemia
-
Jun 5, 2026, 15:10Amna Ahmed: A Step Closer to Solving Bleeding Disorders of Unknown Cause
-
Jun 5, 2026, 14:44Jan T. Kielstein: Bleeding Risk Outweighs Potential Benefits of Rivaroxaban in CKD Patients
-
Jun 5, 2026, 14:31Arwa Z. Al-Riyami: Honored to Serve as ISBT EMR Regional Director
-
Jun 5, 2026, 14:25Bhabajit Patnaik: The End of One Chapter, the Beginning of Another
-
Jun 5, 2026, 14:19Tareq Abadl: The Science of Blood Component Separation and Targeted Transfusion Care